Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™
NASDAQ, TSX: NVCN VANCOUVER, May 6, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read More